sucraloseWhat was measured
Measured, with no finding
168 endpoints
Show what was measuredHide what was measured
cariogenic potential of sucralose-based sweeteners with bulking ingredients versus sugar
decreases
the data suggest that both the currently marketed sucralose granular and packet products are less cariogenic than sugar
PMID 11887514 · one of two readings recorded this
cariogenic potential of sucralose
no effect
The sum of these studies demonstrates that sucralose is non-cariogenic.
PMID 11887514 · one of two readings recorded this
blood glucose
increases, p = 0.05
Blood glucose increased only in response to sucrose (P<0.05)
PMID 19221011 · one of two readings recorded this
gastric emptying t50
Gastric emptying of sucrose was slower than that of saline (t50: 87.4+/-4.1 min vs. 74.7+/-3.2 min, P<0.005)
PMID 19221011 · one of two readings recorded this
gastric emptying t50
no effect
there were no differences in t50 between sucralose 0.4 mM (73.7+/-3.1 min) or 4 mM (76.7+/-3.1 min) and saline
PMID 19221011 · one of two readings recorded this
gastric emptying t50
no effect
there were no differences in t50 between sucralose 0.4 mM (73.7+/-3.1 min) or 4 mM (76.7+/-3.1 min) and saline
PMID 19221011 · one of two readings recorded this
gastric emptying t50
decreases, p = 0.005
Gastric emptying of sucrose was slower than that of saline (t50: 87.4+/-4.1 min vs. 74.7+/-3.2 min, P<0.005)
PMID 19221011 · one of two readings recorded this
plasma GLP-1, GIP and insulin after intragastric infusion
no effect, GLP-1, GIP and insulin increased after sucrose but not after either sucralose load
Not recorded as a finding: plasma-glp-1 is defined for a mixed-nutrient drink or intraduodenal infusion, not an intragastric non-nutrient load; GIP and insulin have no node on this path; abstract-only and the sentence lumps sucralose with saline
GLP-1, GIP, and insulin also increased after sucrose (P=0.0001) but not after either load of sucralose or saline.
PMID 19221011 · one of two readings recorded this
plasma GLP-1, GIP and insulin
no effect
GLP-1, GIP, and insulin also increased after sucrose (P=0.0001) but not after either load of sucralose or saline
PMID 19221011 · one of two readings recorded this
plasma GLP-1, GIP and insulin
increases, p = 0.0001
GLP-1, GIP, and insulin also increased after sucrose (P=0.0001) but not after either load of sucralose or saline
PMID 19221011 · one of two readings recorded this
average plasma GIP concentration
no effect, p = 0.08
Although average plasma GIP concentrations tended to be higher after sucralose than after water ingestion (20 ± 8 vs. 18 ± 7 pmol/L), the difference was not statistically significant (P = 0.08)
PMID 23633524 · one of two readings recorded this
dynamic insulin secretion rate curves
no effect
the dynamic ISR curves were the same after sucralose and water ingestion
PMID 23633524 · one of two readings recorded this
incremental AUC of insulin after a 75 g oral glucose load, immunoenzymatic assay
increases, incremental AUC of insulin 20 +/- 8% greater after sucralose than water
Not recorded as a finding: no outcome node for plasma insulin response to an oral glucose load (stimulated-postprandial-insulin requires an amino-acid preload)
However, the incremental AUC of insulin was 20 ± 8% greater after sucralose than after water ingestion (P < 0.03) (Table 1).
PMID 23633524 · one of two readings recorded this
incremental AUC of plasma glucose after 75 g oral glucose load over 5 h
no effect, no significant differences in incremental AUC of glucose
Not recorded as a finding: postprandial-glucose-auc defines a 60 to 120 minute window; the paper samples to 300 min
No significant differences in the incremental AUC of glucose or C-peptide were detected in response to the glucose load after sucralose and water ingestion.
PMID 23633524 · one of two readings recorded this
incremental AUC of plasma glucose and C-peptide
no effect
No significant differences in the incremental AUC of glucose or C-peptide were detected in response to the glucose load after sucralose and water ingestion
PMID 23633524 · one of two readings recorded this
incremental AUC of plasma glucose over a 5-h 75 g OGTT, YSI analyzer
no effect, no significant difference in incremental glucose AUC after sucralose versus water
Not recorded as a finding: node postprandial-glucose-auc specifies a 60 to 120 minute window; this paper's AUC spans 5 h
No significant differences in the incremental AUC of glucose or C-peptide were detected in response to the glucose load after sucralose and water ingestion.
PMID 23633524 · one of two readings recorded this
incremental AUC of plasma insulin after glucose load
increases, p = 0.03
the incremental AUC of insulin was 20 ± 8% greater after sucralose than after water ingestion (P < 0.03)
PMID 23633524 · one of two readings recorded this
incremental insulin AUC after an oral glucose load, two-site immunoenzymatic assay
increases, incremental AUC of insulin 20 +/- 8% greater after sucralose than water, p = 0.03
Not recorded as a finding: no insulin node for an oral glucose load; stimulated-postprandial-insulin requires an amino-acid preload
However, the incremental AUC of insulin was 20 ± 8% greater after sucralose than after water ingestion (P < 0.03) (Table 1).
PMID 23633524 · one of two readings recorded this
insulin clearance rate after glucose load
decreases, p = 0.05
Sucralose ingestion decreased the insulin clearance rate after ingesting the glucose load by 7 ± 4% (P < 0.05)
PMID 23633524 · one of two readings recorded this
insulin sensitivity index SI from a minimal model of glucose and insulin
decreases, median SI 23 +/- 20% lower after sucralose than water
Not recorded as a finding: no outcome node for minimal-model insulin sensitivity
The median SI value was 23 ± 20% lower after sucralose than after water ingestion (P < 0.01) (Table 1).
PMID 23633524 · one of two readings recorded this
insulin sensitivity index SI from minimal model of glucose and insulin
decreases, median SI 23 +/- 20% lower after sucralose than water, p = 0.01
Not recorded as a finding: no outcome node for minimal-model insulin sensitivity
The median SI value was 23 ± 20% lower after sucralose than after water ingestion (P < 0.01) (Table 1).
PMID 23633524 · one of two readings recorded this
insulin sensitivity index SI (median)
decreases, p = 0.01
The median SI value was 23 ± 20% lower after sucralose than after water ingestion (P < 0.01)
PMID 23633524 · one of two readings recorded this
peak plasma glucose concentration
increases
Mean peak plasma glucose concentration was higher and the subsequent nadir was lower after sucralose than after water ingestion
PMID 23633524 · one of two readings recorded this
peak plasma insulin and C-peptide concentrations
increases
Peak plasma insulin and C-peptide concentrations were also higher after sucralose than after water ingestion
PMID 23633524 · one of two readings recorded this
plasma active GLP-1 and GIP incremental AUC, immunoassay, after 75 g glucose
no effect, not different after sucralose or water ingestion
Not recorded as a finding: plasma-glp-1 and plasma-gip nodes specify a fixed mixed-nutrient drink or intraduodenal infusion, not a 75 g glucose load; the sentence reports two analytes together
Plasma active GLP-1 concentration, incremental GLP-1 AUC, and incremental GIP AUC after the glucose load were not different after sucralose or water ingestion (and Table 1).
PMID 23633524 · one of two readings recorded this
plasma active GLP-1 concentration and incremental GLP-1 AUC after oral glucose load, Meso Scale Discovery immunoassay
no effect, not different after sucralose or water
Not recorded as a finding: plasma-glp-1 is defined after a mixed-nutrient drink or intraduodenal infusion, not an oral glucose load; sentence also lumps GIP AUC
Plasma active GLP-1 concentration, incremental GLP-1 AUC, and incremental GIP AUC after the glucose load were not different after sucralose or water ingestion (and Table 1).
PMID 23633524 · one of two readings recorded this
plasma active GLP-1 concentration, GLP-1 incremental AUC and GIP incremental AUC
no effect
Plasma active GLP-1 concentration, incremental GLP-1 AUC, and incremental GIP AUC after the glucose load were not different after sucralose or water ingestion
PMID 23633524 · one of two readings recorded this
plasma glucagon concentration and decremental glucagon AUC
no effect
Plasma glucagon concentration and the decremental glucagon AUC after the glucose load were similar after sucralose and water ingestion
PMID 23633524 · one of two readings recorded this
static insulin secretion rate between 60 and 105 min
increases, p = 0.005
an average increase of ∼22 ± 4% in the static ISR between 60 and 105 min (P < 0.005)
PMID 23633524 · one of two readings recorded this
total insulin secretion rate AUC and beta-cell sensitivity to glucose (Φtotal, Φdynamic, Φstatic)
no effect
Total ISR AUCs in response to the oral glucose load and the sensitivity of insulin secretion to plasma glucose (Φtotal, Φdynamic, and Φstatic) were not different between sucralose and water conditions (Table 1)
PMID 23633524 · one of two readings recorded this
participants with detectable urinary sucralose after intervention
unclear, n = 3
sucralose was detected in 3 individuals randomly assigned to receive carbonated water (26-121 ng/mL; mean ± SD: 60.7 ± 52.4 ng/mL)
PMID 28228424 · one of two readings recorded this
participants with detectable urinary sucralose after run-in
unclear, n = 8
sucralose was found in 8 individuals (2 of whom did not have detectable sucralose at baseline) and ranged from 25.0 to 1062.0 ng/mL (mean ± SD: 191.7 ± 354.2 ng/mL)
PMID 28228424 · one of two readings recorded this
participants with detectable urinary sucralose at baseline
unclear, n = 8
At baseline, 8 participants had sucralose in their urine (29.9-239.0 ng/mL; mean ± SD: 111.4 ± 91.5 ng/mL)
PMID 28228424 · one of two readings recorded this
active GLP-1 AUC
increases, p = 0.001, n = 15
AUC of active GLP-1 was significantly higher in the sucralose than placebo (23.16 ± 18.86 versus 18.5 ± 22.22 pmol/L ⋅ 120 min, P < 0.001)
PMID 30005329 · one of two readings recorded this
acute insulin response (AIR) to glucose on IVGTT; Matsuda index; AUC of active GLP-1 after a 75 g OGTT, 200 mg sucralose pills versus placebo for 4 wk, crossover
decreases, AIR 58.9 +/- 48.61 versus 69.94 +/- 73.81 uU/mL on sucralose versus placebo
Not recorded as a finding: this platform holds no node for the endpoint
AIR was lower after exposure to sucralose than placebo (58.9 ± 48.61 versus 69.94 ± 73.81 µU/mL, P < 0.001).
PMID 30005329 · one of two readings recorded this
acute insulin response to glucose (AIR)
decreases, p = 0.001, n = 15
AIR was lower after exposure to sucralose than placebo (58.9 ± 48.61 versus 69.94 ± 73.81 µU/mL, P < 0.001)
PMID 30005329 · one of two readings recorded this
whole-body insulin sensitivity by Matsuda index from a 75 g OGTT after 4 weeks of 200 mg sucralose pills versus placebo; acute insulin response on IVGTT; active GLP-1 AUC
decreases, Matsuda index 4.69 ± 1.67 with sucralose versus 5.31 ± 2.56 with placebo
Not recorded as a finding: this platform holds no node for the endpoint
Whole-body insulin sensitivity (estimated using the Matsuda index) was lower in sucralose than placebo (4.69 ± 1.67 versus 5.31 ± 2.56, P < 0.005).
PMID 30005329 · one of two readings recorded this
whole-body insulin sensitivity
decreases, p = 0.005, n = 15
Whole-body insulin sensitivity (estimated using the Matsuda index) was lower in sucralose than placebo (4.69 ± 1.67 versus 5.31 ± 2.56, P < 0.005)
PMID 30005329 · one of two readings recorded this
acute insulin response to glucose
increases, p = 0.04
An increased acute insulin response to glucose from 577 mU · L-1· min (350-1040 mU · L-1· min) to 671 mU · L-1· min (376-1010 mU · L-1· min) (P = 0.04)
PMID 30535090 · one of two readings recorded this
insulin sensitivity, acute insulin response to glucose, disposition index and glucose effectiveness by 3-h modified intravenous glucose tolerance test, 15% of Acceptable Daily Intake sucralose for 14 d versus no-intervention control
decreases, median percentage change in insulin sensitivity -17.7% versus -2.8% in control, p = 0.04
Not recorded as a finding: this platform holds no node for the endpoint
Individuals assigned to sucralose consumption showed a significant decrease in insulin sensitivity with a median (IQR) percentage change of -17.7% (-29.3% to -1.0%) in comparison to -2.8% (-30.7% to 40.6%) in the control group (P= 0.04).
PMID 30535090 · one of two readings recorded this
insulin sensitivity from a 3-h modified intravenous glucose tolerance test, sucralose 15% of ADI for 14 d versus a no-intervention control group
decreases, median percentage change -17.7% (-29.3% to -1.0%) versus -2.8% (-30.7% to 40.6%) in controls, p = 0.04
Not recorded as a finding: this platform holds no node for the endpoint
Individuals assigned to sucralose consumption showed a significant decrease in insulin sensitivity with a median (IQR) percentage change of -17.7% (-29.3% to -1.0%) in comparison to -2.8% (-30.7% to 40.6%) in the control group (P= 0.04).
PMID 30535090 · one of two readings recorded this
insulin sensitivity percentage change
a median (IQR) percentage change of -17.7% (-29.3% to -1.0%) in comparison to -2.8% (-30.7% to 40.6%) in the control group (P= 0.04)
PMID 30535090 · one of two readings recorded this
insulin sensitivity percentage change
decreases, p = 0.04, n = 66
a median (IQR) percentage change of -17.7% (-29.3% to -1.0%) in comparison to -2.8% (-30.7% to 40.6%) in the control group (P= 0.04)
PMID 30535090 · one of two readings recorded this
blood glucose during OGTT
no effect
Blood glucose values showed no significant differences in subjects receiving placebo or sucralose all along the oral glucose tolerance test
PMID 31183389 · one of two readings recorded this
CD11c expression on classical monocytes, -15 min versus 180 min
decreases, p = 0.0008
In classical monocytes, CD11c expression significantly diminished in the sucralose group at the beginning (-15 min) and at the end (180 min) of the OGTT (P = 0.0008)
PMID 31183389 · one of two readings recorded this
CD11c expression on intermediate monocytes, -15 min versus 180 min
decreases, p = 0.0004
CD11c expression also exhibited a significant reduction in intermediate and nonclassical monocytes of subjects exposed to sucralose at the beginning (-15 min) and at the end (180 min) of the OGTT (P = 0.0004 and P = 0.0001, respectively)
PMID 31183389 · one of two readings recorded this
CD11c expression on intermediate monocytes at 180 min
decreases, p = 0.0012
At 180 min, CD11c expression was significantly reduced in intermediate and nonclassical monocytes of subjects receiving sucralose as compared to placebo controls (P = 0.0012 and P = 0.0064, respectively)
PMID 31183389 · one of two readings recorded this
CD11c expression on nonclassical monocytes, -15 min versus 180 min
decreases, p = 0.0001
CD11c expression also exhibited a significant reduction in intermediate and nonclassical monocytes of subjects exposed to sucralose at the beginning (-15 min) and at the end (180 min) of the OGTT (P = 0.0004 and P = 0.0001, respectively)
PMID 31183389 · one of two readings recorded this
CD11c expression on nonclassical monocytes at 180 min
decreases, p = 0.0064
At 180 min, CD11c expression was significantly reduced in intermediate and nonclassical monocytes of subjects receiving sucralose as compared to placebo controls (P = 0.0012 and P = 0.0064, respectively)
PMID 31183389 · one of two readings recorded this
CD206 expression on nonclassical monocytes at 180 min
decreases, p = 0.0098
At 180 min, CD206 expression was significantly reduced in nonclassical monocytes of volunteers that received sucralose as compared to placebo controls (P = 0.0098)
PMID 31183389 · one of two readings recorded this
classical monocyte percentage at 180 min
increases, p = 0.0028
a significant 7% increase in the number of classical monocytes from subjects that received sucralose in comparison to controls receiving placebo (P = 0.0028)
PMID 31183389 · one of two readings recorded this
correlation of blood glucose with monocyte subpopulations
no effect
Analysis of Pearson's correlation coefficients showed no significant associations of monocyte subpopulations with blood glucose (Table 2)
PMID 31183389 · one of two readings recorded this
correlation of serum insulin with classical monocytes
increases, p = 0.02
serum insulin showed a positive relationship with classical monocytes (r = 0.41, P = 0.02)
PMID 31183389 · one of two readings recorded this
correlation of serum insulin with nonclassical monocytes
decreases, p = 0.01
it also exhibited a strong inverse association with nonclassical monocytes (r = −0.42, P = 0.01)
PMID 31183389 · one of two readings recorded this
intermediate monocyte percentage at 180 min
no effect
No significant differences were found in the percentage of intermediate monocytes in subjects that received placebo or sucralose
PMID 31183389 · one of two readings recorded this
nonclassical monocyte percentage at 180 min
decreases, p = 0.0001
the nonclassical monocyte percentage exhibited a significant 63% reduction in subjects exposed to sucralose with respect to placebo controls (P < 0.0001)
PMID 31183389 · one of two readings recorded this
serum insulin at timepoints of a 180-min OGTT, ELISA; blood glucose at OGTT timepoints; monocyte subpopulation percentages (classical, intermediate, nonclassical) by flow cytometry
increases, 1.3-fold increase in serum insulin at 30 min versus placebo, p = 0.041
Not recorded as a finding: this platform holds no node for the endpoint
On the contrary, volunteers that received 48 mg sucralose prior glucose load showed a significant 1.3-fold increase in the serum levels of insulin at 30 min as compared to subjects drinking water as placebo (P = 0.041).
PMID 31183389 · one of two readings recorded this
serum insulin during OGTT after a 48 mg sucralose sip versus water, ELISA; monocyte subpopulation percentages (CD14/CD16) by flow cytometry
decreases, significant 63% reduction in nonclassical monocyte percentage versus placebo
Not recorded as a finding: this platform holds no node for the endpoint
On the other side, the nonclassical monocyte percentage exhibited a significant 63% reduction in subjects exposed to sucralose with respect to placebo controls (P < 0.0001).
PMID 31183389 · one of two readings recorded this
serum insulin during OGTT at 180 min
increases, p = 0.048
At 180 min, subjects that received sucralose showed a significant 2-fold increase in the serum levels of insulin as compared to placebo controls (P = 0.048)
PMID 31183389 · one of two readings recorded this
serum insulin during OGTT at 30 min
increases, p = 0.041
volunteers that received 48 mg sucralose prior glucose load showed a significant 1.3-fold increase in the serum levels of insulin at 30 min as compared to subjects drinking water as placebo (P = 0.041)
PMID 31183389 · one of two readings recorded this
serum insulin during OGTT at 45 min
increases, p = 0.046
At 45 min, subjects receiving sucralose exhibited a significant 1.4-fold elevation in serum insulin with respect to placebo controls (P = 0.046)
PMID 31183389 · one of two readings recorded this
Bacteroidetes and Firmicutes abundance
modulates
Independent of consuming sucralose or placebo, individuals with a higher insulinaemic response after the intervention had lower Bacteroidetes and higher Firmicutes abundances
PMID 31258108 · one of two readings recorded this
body weight
no effect
During the study, body weight remained constant in both groups
PMID 31258108 · one of two readings recorded this
glycaemic control and insulin resistance (HOMA-IR, Matsuda index)
no effect
Glycaemic control and insulin resistance were not affected during the 7-d period
PMID 31258108 · one of two readings recorded this
gut microbiome at phylum level
no effect
At the phylum level, gut microbiome was not modified in any group
PMID 31258108 · one of two readings recorded this
insulin resistance by HOMA-IR and Matsuda indexes after a 75 g oral glucose load; glycaemic and insulinaemic responses; gut microbiome by 16S rRNA sequencing; sucralose capsules 780 mg/d for 7 d versus placebo
no effect, no alteration of glycaemic control, insulin resistance or gut microbiome
Not recorded as a finding: a node exists but the paper states a different instrument or population
In conclusion, consumption of high doses of sucralose for 7 d does not alter glycaemic control, insulin resistance, or gut microbiome in healthy individuals.
PMID 31258108 · one of two readings recorded this
dynamic insulin secretion rate, treatment by weight group by time interaction
modulates, p = 0.02
Sucralose modified the ISR dynamic response to the glucose load only in the group with obesity (Treatment × Weight Group × Time: F(20,360) = 2.19; p < 0.02
PMID 31877631 · one of two readings recorded this
endogenous glucose production suppression by glucose ingestion, obesity versus normal weight
increases, p = 0.018
Glucose ingestion suppressed EGP rapidly in both groups (p < 0.0001), but more so in participants with obesity (p = 0.018
PMID 31877631 · one of two readings recorded this
insulin clearance rate after glucose load
no effect, p = 0.08
Ingested sucralose and sham-fed sucralose tended to increase the insulin clearance rate after ingesting the glucose load (p = 0.08; Table 2)
PMID 31877631 · one of two readings recorded this
insulin clearance rate, obesity versus normal weight
decreases, p = 0.09
Participants with obesity were less insulin sensitive (p < 0.0005) and tended to have a slower rate of insulin clearance (p = 0.09) than normal-weight participants
PMID 31877631 · one of two readings recorded this
insulin sensitivity SI, obesity versus normal weight
decreases, p = 0.0005
Participants with obesity were less insulin sensitive (p < 0.0005) and tended to have a slower rate of insulin clearance (p = 0.09) than normal-weight participants
PMID 31877631 · one of two readings recorded this
insulin sensitivity SI, treatment by weight group interaction
modulates, p = 0.02
Sucralose differentially affected SI in participants with obesity and in normal-weight participants (Treatment × Weight- group: F(2,36) = 4.32; p < 0.02)
PMID 31877631 · one of two readings recorded this
insulin sensitivity SI
increases, p = 0.05
Compared with water, sucralose increased SI by 52 ± 21% in normal-weight participants (p < 0.05)
PMID 31877631 · one of two readings recorded this
insulin sensitivity SI
no effect, p = 0.18
Sham-fed sucralose also increased SI by 27 ± 13% in this group, but the difference from water treatment was not statistically significant (p = 0.18)
PMID 31877631 · one of two readings recorded this
oral glucose rate of appearance during first 40 min of OGTT, weight group by time
increases, p = 0.04
Participants with obesity had a higher oral glucose rate of appearance during the first 40 min of the OGTT than normal-weight participants (Weight Group × Time: F(11,209) = 1.88, p = 0.04
PMID 31877631 · one of two readings recorded this
peak plasma glucose, obesity versus normal weight
decreases, p = 0.06
the peak response in plasma glucose concentrations tended to be lower in participants with obesity than in normal-weight participants (p = 0.06
PMID 31877631 · one of two readings recorded this
peak plasma sucralose concentration, obesity versus normal weight
no effect, p = 0.31
no significant differences between weight groups on peak sucralose concentrations (p = 0.31), time to peak (p = 0.11), or sucralose iAUC (p = 0.90
PMID 31877631 · one of two readings recorded this
plasma C-peptide concentrations, treatment by weight group by time interaction
no effect, p = 0.06
the interaction between treatment, weight group, and time was not statistical significant (F(40,720) = 1.37; p = 0.06; Figure 1)
PMID 31877631 · one of two readings recorded this
plasma GIP concentration 10 min post-OGTT, ingested versus sham-fed sucralose
modulates, p = 0.001
ingested sucralose affected plasma GIP concentrations 10 min post-OGTT in both weight groups, but in opposite ways (Treatment × Weight Group × Time: F(18,323) = 2.55; p < 0.001)
PMID 31877631 · one of two readings recorded this
plasma glucose iAUC during OGTT
increases, p = 0.03
Sucralose ingested, but not sham-fed, increased the iAUC of plasma glucose by 30 ± 10% in both weight groups similarly (Treatment: F(2,36) = 3.99; p = 0.03
PMID 31877631 · one of two readings recorded this
plasma insulin and C-peptide mean, peak and iAUC, obesity versus normal weight
increases, p = 0.02
Plasma insulin and C-peptide mean and peak concentrations, as well as iAUCs, were significantly higher in participants with obesity than in normal-weight participants (all p-values < 0.02
PMID 31877631 · one of two readings recorded this
plasma insulin concentrations during first hour of OGTT
decreases
Compared with water treatment, sham-fed sucralose similarly reduced plasma insulin concentrations within the first hour of the OGTT in both weight groups
PMID 31877631 · one of two readings recorded this
plasma insulin concentrations, treatment by weight group by time interaction
modulates, p = 0.009
whereas sucralose ingestion differentially affected insulin concentrations in the two weight groups (Treatment × Weight Group × Time: F(40,720) = 1.63; p = 0.009; Figure 1)
PMID 31877631 · one of two readings recorded this
plasma sucralose concentration during last hour of OGTT, weight group by time
increases, p = 0.004
Participants with obesity had higher plasma sucralose concentrations than did normal-weight participants during the last hour of the OGTT (Weight Group x Time: F(9,162) = 2.98, p = 0.004
PMID 31877631 · one of two readings recorded this
plasma sucralose iAUC, obesity versus normal weight
no effect, p = 0.9
no significant differences between weight groups on peak sucralose concentrations (p = 0.31), time to peak (p = 0.11), or sucralose iAUC (p = 0.90
PMID 31877631 · one of two readings recorded this
time to peak plasma sucralose, obesity versus normal weight
no effect, p = 0.11
no significant differences between weight groups on peak sucralose concentrations (p = 0.31), time to peak (p = 0.11), or sucralose iAUC (p = 0.90
PMID 31877631 · one of two readings recorded this
total and oral glucose rate of appearance
no effect
Sucralose, ingested or sham-fed, did not affect the total glucose rate of appearance or the oral glucose rate of appearance in either weight group
PMID 31877631 · one of two readings recorded this
total and static insulin secretion rate and beta-cell glucose sensitivity
no effect
Treatment did not significantly affect the sensitivity of insulin secretion to plasma glucose or total or static ISR responses during the OGTT in either weight group
PMID 31877631 · one of two readings recorded this
total, dynamic and static insulin secretion rate, obesity versus normal weight
increases, p = 0.05
Total, dynamic, and static ISR and the sensitivity of insulin secretion to plasma glucose in response to the OGTT were significantly higher in participants with obesity than in normal-weight participants across all treatments (all p < 0.05
PMID 31877631 · one of two readings recorded this
adherence to intervention
no effect, p = 0.16
Adherence to intervention (%) | 94.14 ± 11.81 | 86.07 ± 19.12 | 87 ± 20.37 | 0.16
PMID 32284053 · one of two readings recorded this
adherence to intervention
no effect
Adherence to intervention (%) | 94.14 ± 11.81 | 86.07 ± 19.12 | 87 ± 20.37 | 0.16
PMID 32284053 · one of two readings recorded this
adherence to intervention
no effect
Adherence to intervention (%) | 94.14 ± 11.81 | 86.07 ± 19.12 | 87 ± 20.37 | 0.16
PMID 32284053 · one of two readings recorded this
blood glucose during OGTT at 0 min, Wk10 vs Wk0
increases, p = 0.04
at 0 min (88.7 ± 4 mg/dL vs. 91.3 ± 6 mg/dL; p = 0.04)
PMID 32284053 · one of two readings recorded this
blood glucose during OGTT at 120 min, Wk10 vs Wk0
increases, p = 0.01
at 120 min (95.2 ± 23.7 mg/dL vs 106.9 ± 19.5 mg/dL; p = 0.01)
PMID 32284053 · one of two readings recorded this
blood glucose during OGTT at -15 min, Wk10 vs Wk0
increases, p = 0.003
at − 15 min (87.9 ± 4.6 mg/dL vs 91.4 ± 5.4 mg/dL; p = 0.003)
PMID 32284053 · one of two readings recorded this
BMI, Wk10 vs Wk0
no effect, p = 0.47
48 mg sucralose | 24.2 ± 2.9 | 24.2 ± 3.1 | 0.47
PMID 32284053 · one of two readings recorded this
BMI, Wk10 vs Wk0
no effect, p = 0.56
96 mg sucralose | 23.7 ± 3.3 | 23.6 ± 3.2 | 0.56
PMID 32284053 · one of two readings recorded this
BMI, Wk10 vs Wk0
no effect, p = 0.32
Control | 24.2 ± 3.8 | 24.1 ± 3.9 | 0.32
PMID 32284053 · one of two readings recorded this
carbohydrate intake, Wk10 vs Wk0
no effect, p = 0.18
48 mg sucralose | 227.9 ± 59.3 | 252.9 ± 86.7 | 0.18
PMID 32284053 · one of two readings recorded this
carbohydrate intake, Wk10 vs Wk0
no effect, p = 0.42
96 mg sucralose | 264.7 ± 133.9 | 286.5 ± 132.7 | 0.42
PMID 32284053 · one of two readings recorded this
carbohydrate intake, Wk10 vs Wk0
no effect, p = 0.12
Control | 289.4 ± 118.4 | 250.7 ± 123.5 | 0.12
PMID 32284053 · one of two readings recorded this
energy intake, Wk10 vs Wk0
no effect, p = 0.1
48 mg sucralose | 1935.9 ± 681.8 | 2170.7 ± 732.3 | 0.10
PMID 32284053 · one of two readings recorded this
energy intake, Wk10 vs Wk0
no effect, p = 0.65
96 mg sucralose | 2133.1 ± 965.8 | 2235.7 ± 917.5 | 0.65
PMID 32284053 · one of two readings recorded this
energy intake, Wk10 vs Wk0
no effect, p = 0.09
Control | 22 64.8 ± 1247.2 | 1941.6 ± 710.7 | 0.09
PMID 32284053 · one of two readings recorded this
glucose AUC, any sucralose group, Wk10 vs Wk0
increases, p = 0.01
for glucose, Wk0 = 18,141 ± 3877 vs Wk10 = 18,885 ± 3332, p = 0.01
PMID 32284053 · one of two readings recorded this
glucose AUC, Bonferroni difference 48 mg vs 96 mg
no effect, p = 0.29
96 mg | 1027.96 | 617.01 | 0.29 | −462.79 | 2518.70
PMID 32284053 · one of two readings recorded this
glucose AUC, Bonferroni difference 48 mg vs control
increases, p = 0.03
Glucose, AUC | Control | 48 mg | -1537.81 | 603.48 | 0.03a | -2995.85 | −79.77
PMID 32284053 · one of two readings recorded this
glucose AUC, Bonferroni difference 96 mg vs control
no effect, p = 1
96 mg | − 509.85 | 598.28 | 1.00 | − 1955.34 | 935.64
PMID 32284053 · one of two readings recorded this
glucose AUC, type-by-time interaction
no effect, p = 1
No interaction between type of intervention (control, 48 mg or 96 mg sucralose) and consumption time (Wk0 and Wk10) was found in glucose AUC (F(2,184) = 0.00, p = 1.00)
PMID 32284053 · one of two readings recorded this
glucose AUC, type of intervention main effect
modulates, p = 0.038
type of intervention showed a significant effect (F(2,184) = 3.327, p = 0.038, η2 = 0.035, 1-β = 0.624)
PMID 32284053 · one of two readings recorded this
glucose AUC, Wk10 vs Wk0
no effect, p = 0.05
48 mg sucralose | 18,267 ± 2858 | 19,408 ± 2904 | 0.05
PMID 32284053 · one of two readings recorded this
glucose AUC, Wk10 vs Wk0
no effect, p = 0.66
96 mg sucralose | 18,019 ± 4705 | 18,380 ± 3677 | 0.66
PMID 32284053 · one of two readings recorded this
glucose AUC, Wk10 vs Wk0
no effect, p = 0.91
Control | 17,820 ± 2872 | 17,870 ± 3557 | 0.91
PMID 32284053 · one of two readings recorded this
HbA1c, Wk10 vs Wk0
no effect, p = 0.51
48 mg sucralose | 5.23 ± 0.21 | 5.26 ± 0.26 | 0.51
PMID 32284053 · one of two readings recorded this
HbA1c, Wk10 vs Wk0
increases, p = 0.03
96 mg sucralose | 5.15 ± 0.3 | 5.25 ± 0.26 | 0.03
PMID 32284053 · one of two readings recorded this
HbA1c, Wk10 vs Wk0
no effect, p = 0.55
Control | 5.22 ± 0.23 | 5.24 ± 0.24 | 0.55
PMID 32284053 · one of two readings recorded this
insulin AUC, any sucralose group, Wk10 vs Wk0
increases, p = 0.006
for insulin, Wk0 = 8093 ± 4687 vs Wk10 = 9871 ± 6253, p = 0.006
PMID 32284053 · one of two readings recorded this
insulin AUC at Wk0, 96 mg versus 48 mg
no effect, p = 0.06
AUC Wk0 96 mg = 6962 ± 4899 vs AUC Wk0 48 mg = 9262 ± 4225; p = 0.06
PMID 32284053 · one of two readings recorded this
insulin AUC at Wk10, 48 mg versus control
no effect, p = 0.07
AUC Wk10 48 mg = 11,398 ± 6641 vs AUC Wk10 control = 9397 ± 5126; p = 0.07
PMID 32284053 · one of two readings recorded this
insulin AUC at Wk10, 96 mg versus 48 mg
no effect, p = 0.06
AUC Wk10 96 mg = 8394 ± 5567 vs AUC Wk10 48 mg = 11,398 ± 6641 p = 0.06
PMID 32284053 · one of two readings recorded this
insulin AUC, Bonferroni difference 48 mg vs 96 mg
increases, p = 0.02
96 mg | 2652.20a | 975.45 | 0.02 | 295.45 | 5008.96
PMID 32284053 · one of two readings recorded this
insulin AUC, Bonferroni difference 48 mg vs control
no effect, p = 0.75
Insulin, AUC | Control | 48 mg | − 1104.65 | 954.05 | 0.75 | − 3409.70 | 1200.40
PMID 32284053 · one of two readings recorded this
insulin AUC, Bonferroni difference 96 mg vs control
no effect, p = 0.31
96 mg | 1547.55 | 945.84 | 0.31 | − 737.66 | 3832.77
PMID 32284053 · one of two readings recorded this
insulin AUC, consumption time main effect (Wk0 vs Wk10)
no effect, p = 0.1
it showed a tendency to increase (F(1,184) = 2.77, p = 0.10)
PMID 32284053 · one of two readings recorded this
insulin AUC, type-by-time interaction
no effect, p = 0.63
no interaction between type of intervention and consumption time was observed (F(2,184) = 0.45, p = 0.63)
PMID 32284053 · one of two readings recorded this
insulin AUC, type of intervention main effect
modulates, p = 0.03
type of intervention had a significant effect on the AUC of insulin (F(2,184) = 3.74, p = 0.03, η2 = 0.039, 1-β = 0.679)
PMID 32284053 · one of two readings recorded this
insulin AUC, Wk10 vs Wk0
increases, p = 0.02
48 mg sucralose | 9262 ± 4225 | 11,398 ± 6641 | 0.02
PMID 32284053 · one of two readings recorded this
insulin AUC, Wk10 vs Wk0
no effect, p = 0.12
96 mg sucralose | 6962 ± 4899 | 8394 ± 5567 | 0.12
PMID 32284053 · one of two readings recorded this
insulin AUC, Wk10 vs Wk0
no effect, p = 0.65
Control | 9054 ± 5571 | 9397 ± 5126 | 0.65
PMID 32284053 · one of two readings recorded this
lipid intake, Wk10 vs Wk0
no effect, p = 0.1
48 mg sucralose | 67.6 ± 43.4 | 81.6 ± 40.4 | 0.10
PMID 32284053 · one of two readings recorded this
lipid intake, Wk10 vs Wk0
no effect, p = 0.63
96 mg sucralose | 69.2 ± 43.4 | 74.2 ± 40.9 | 0.63
PMID 32284053 · one of two readings recorded this
lipid intake, Wk10 vs Wk0
no effect, p = 0.29
Control | 71.6 ± 59.9 | 62.1 ± 26.6 | 0.29
PMID 32284053 · one of two readings recorded this
Matsuda insulin sensitivity index, Wk10 vs Wk0
decreases, p = 0.01
48 mg sucralose | 6.04 ± 3.19 | 4.86 ± 2.13 | 0.01
PMID 32284053 · one of two readings recorded this
Matsuda insulin sensitivity index, Wk10 vs Wk0
no effect, p = 0.3
96 mg sucralose | 7.93 ± 4.63 | 7.09 ± 4.72 | 0.30
PMID 32284053 · one of two readings recorded this
Matsuda insulin sensitivity index, Wk10 vs Wk0
no effect, p = 0.09
Control | 6.8 ± 3.35 | 6.14 ± 3.41 | 0.09
PMID 32284053 · one of two readings recorded this
maximum glucose concentration in OGTT, Wk10 vs Wk0
no effect, p = 0.09
48 mg sucralose | 133.06 ± 20.79 | 141.17 ± 18.59 | 0.09
PMID 32284053 · one of two readings recorded this
maximum glucose concentration in OGTT, Wk10 vs Wk0
no effect, p = 0.46
96 mg sucralose | 133.45 ± 29.72 | 137.61 ± 25.33 | 0.46
PMID 32284053 · one of two readings recorded this
maximum glucose concentration in OGTT, Wk10 vs Wk0
no effect, p = 0.41
Control | 131.94 ± 21.19 | 135.12 ± 23.53 | 0.41
PMID 32284053 · one of two readings recorded this
maximum insulin concentration in OGTT, Wk10 vs Wk0
increases, p = 0.01
48 mg sucralose | 106.10 ± 58 | 130.9 ± 60.51 | 0.01
PMID 32284053 · one of two readings recorded this
maximum insulin concentration in OGTT, Wk10 vs Wk0
no effect, p = 0.48
96 mg sucralose | 85.42 ± 42.67 | 90.42 ± 50.41 | 0.48
PMID 32284053 · one of two readings recorded this
maximum insulin concentration in OGTT, Wk10 vs Wk0
no effect, p = 0.34
Control | 100 ± 56.07 | 108.94 ± 62.15 | 0.34
PMID 32284053 · one of two readings recorded this
protein intake, Wk10 vs Wk0
no effect, p = 0.86
48 mg sucralose | 94.4 ± 60.6 | 97.47 ± 44.4 | 0.86
PMID 32284053 · one of two readings recorded this
protein intake, Wk10 vs Wk0
no effect, p = 0.32
96 mg sucralose | 100.8 ± 44.4 | 94.9 ± 82.9 | 0.32
PMID 32284053 · one of two readings recorded this
protein intake, Wk10 vs Wk0
no effect, p = 0.09
Control | 103.9 ± 74.8 | 84.7 ± 32.9 | 0.09
PMID 32284053 · one of two readings recorded this
serum insulin during OGTT at 0 min, Wk10 vs Wk0
increases, p = 0.01
at 0 min (7.5 ± 3.4 μIU/mL vs 8.8 ± 4.1 μIU/mL; p = 0.01)
PMID 32284053 · one of two readings recorded this
serum insulin during OGTT at 105 min, Wk10 vs Wk0
increases, p = 0.04
at 105 min (47.7 ± 24.4 μIU/mL vs. 64.3 ± 48.2 μIU/mL; p = 0.04)
PMID 32284053 · one of two readings recorded this
serum insulin during OGTT at 120 min, Wk10 vs Wk0
increases, p = 0.01
at 120 min (44.8 ± 22.1 μIU/mL vs. 63.1 ± 47.8 μIU/mL; p = 0.01)
PMID 32284053 · one of two readings recorded this
serum insulin during OGTT at 30 min, Wk10 vs Wk0
increases, p = 0.05
at 30 min (91.3 ± 56.2 μIU/mL vs. 110.1 ± 49.4 μIU/mL; p = 0.05)
PMID 32284053 · one of two readings recorded this
time to maximum glucose in OGTT, Wk10 vs Wk0
no effect, p = 0.11
48 mg sucralose | 34 ± 18.45 | 40.5 ± 23.35 | 0.11
PMID 32284053 · one of two readings recorded this
time to maximum glucose in OGTT, Wk10 vs Wk0
no effect, p = 0.58
96 mg sucralose | 36.77 ± 20.06 | 34.84 ± 19.51 | 0.58
PMID 32284053 · one of two readings recorded this
time to maximum glucose in OGTT, Wk10 vs Wk0
no effect, p = 1
Control | 36.18 ± 9.85 | 36.18 ± 20.27 | 1.00
PMID 32284053 · one of two readings recorded this
time to maximum insulin in OGTT, Wk10 vs Wk0
no effect, p = 0.58
48 mg sucralose | 40.5 ± 14.82 | 38.5 ± 20.35 | 0.58
PMID 32284053 · one of two readings recorded this
time to maximum insulin in OGTT, Wk10 vs Wk0
no effect, p = 0.23
96 mg sucralose | 40.65 ± 17.4 | 45.48 ± 17.53 | 0.23
PMID 32284053 · one of two readings recorded this
time to maximum insulin in OGTT, Wk10 vs Wk0
no effect, p = 0.5
Control | 45 ± 19.19 | 48.09 ± 23.87 | 0.50
PMID 32284053 · one of two readings recorded this
fasting plasma GLP-1, ghrelin, PYY and leptin
no effect
Sucralose intake is not associated with changes in fasting concentrations of glucagon-like peptide 1, ghrelin, peptide tyrosine tyrosine, or leptin
PMID 32711853 · one of two readings recorded this
HOMA-IR, repeated measures ANOVA, one week after dosing ended
increases, incremental change in HOMA-IR in the intervention group, p = 0.04
Not recorded as a finding: the abstract reports a change in the intervention group only, with no between-arm statement, and the sentence does not name sucralose
One week postintervention, an incremental change (P=0.04) in the homeostasis model assessment of insulin resistance was found in the intervention group.
PMID 32711853 · one of two readings recorded this
HOMA-IR, repeated-measures ANOVA, secondary outcome
increases, incremental change in HOMA-IR one week postintervention in the intervention group, p = 0.04
Not recorded as a finding: result is a within-group change at one week post-dosing only, with no between-arm sentence, and the abstract states it of unknown clinical significance
One week postintervention, an incremental change (P=0.04) in the homeostasis model assessment of insulin resistance was found in the intervention group.
PMID 32711853 · one of two readings recorded this
homeostasis model assessment of insulin resistance
increases, p = 0.04
One week postintervention, an incremental change (P=0.04) in the homeostasis model assessment of insulin resistance was found in the intervention group
PMID 32711853 · one of two readings recorded this
glucose, insulin and GLP-1 areas under the curve after MMTT
increases
Glucose, insulin and GLP-1 areas under the curve increased after the MMTT, along with a significant decrease in insulin sensitivity after sucralose consumption
PMID 40907790 · one of two readings recorded this
gut microbiota alpha-diversity
decreases
A reduction in α-diversity of the gut microbiota was observed
PMID 40907790 · one of two readings recorded this
insulin sensitivity by Matsuda index after a mixed meal tolerance test, 30 % of sucralose acceptable daily intake for 30 days versus placebo; also glucose, insulin and GLP-1 AUC, gut microbiota alpha-diversity, fecal Curli protein
decreases, 20.3 % decrease in insulin sensitivity
Not recorded as a finding: this platform holds no node for the endpoint
The consumption of sucralose in healthy lean individuals for 30 days caused a 20.3 % significant decrease in insulin sensitivity.
PMID 40907790 · one of two readings recorded this
insulin sensitivity by Matsuda index during a mixed meal tolerance test, after 30 days of sucralose versus placebo
decreases, 20.3 % significant decrease in insulin sensitivity
Not recorded as a finding: this platform holds no node for the endpoint
The consumption of sucralose in healthy lean individuals for 30 days caused a 20.3 % significant decrease in insulin sensitivity.
PMID 40907790 · one of two readings recorded this
insulin sensitivity
decreases
The consumption of sucralose in healthy lean individuals for 30 days caused a 20.3 % significant decrease in insulin sensitivity
PMID 40907790 · one of two readings recorded this
proinflammatory markers, BCAA, acetate and fecal Curli protein
increases
proinflammatory markers, BCAA, acetate, and fecal Curli protein increased, whereas serum glutamic acid and fecal butyrate, decreased after sucralose consumption
PMID 40907790 · one of two readings recorded this
serum glutamic acid and fecal butyrate
decreases
proinflammatory markers, BCAA, acetate, and fecal Curli protein increased, whereas serum glutamic acid and fecal butyrate, decreased after sucralose consumption
PMID 40907790 · one of two readings recorded this
faecal/serum butyrate concentration
no effect, numerical decrease, pooled effect not statistically significant, substantial heterogeneity
Butyrate showed a numerical decrease, although the pooled effect was not statistically significant and substantial heterogeneity was observed.
PMID 42794802 · one of two readings recorded this
pooled faecal/serum butyrate, short-chain fatty acid production
no effect, numerical decrease, pooled effect not statistically significant, substantial heterogeneity
Not recorded as a finding: no outcome node for short-chain fatty acid production
Butyrate showed a numerical decrease, although the pooled effect was not statistically significant and substantial heterogeneity was observed.
PMID 42794802 · one of two readings recorded this
pooled short-chain fatty acid, butyrate
Not recorded as a finding: no outcome node exists for short-chain fatty acids/butyrate; also no quantitative estimate stated for this endpoint in the abstract
Butyrate showed a numerical decrease, although the pooled effect was not statistically significant and substantial heterogeneity was observed.
PMID 42794802 · one of two readings recorded this